# Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

> **NCT02676349** · PHASE2 · COMPLETED · sponsor: **Institut de Cancérologie de Lorraine** · enrollment: 130 (actual)

## Conditions studied

- Pancreatic Carcinoma

## Interventions

- **DRUG:** mFolfirinox
- **RADIATION:** Chemoradiotherapy
- **PROCEDURE:** surgery
- **DRUG:** Adjuvant chemotherapy

## Key facts

- **NCT ID:** NCT02676349
- **Lead sponsor:** Institut de Cancérologie de Lorraine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-13
- **Primary completion:** 2024-04-19
- **Final completion:** 2025-12
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02676349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02676349, "Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02676349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*